Arcturus Therapeutics to Present at Upcoming Investor Conferences
February 11, 2019 07:05 ET
|
Arcturus Therapeutics, Inc.
SAN DIEGO, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards rare,...
Arcturus Therapeutics Reassumes Full Worldwide Rights to ARCT-810, a Clinical Development Candidate for Ornithine Transcarbamylase (OTC) Deficiency
February 11, 2019 07:00 ET
|
Arcturus Therapeutics, Inc.
SAN DIEGO, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the discovery, development and commercialization of therapeutics...
Arcturus Therapeutics Appoints Andrew Sassine as Chief Financial Officer
January 03, 2019 07:00 ET
|
Arcturus Therapeutics, Inc.
SAN DIEGO, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards rare,...
Arcturus Therapeutics to Develop ARCT-810 for Treatment of Ornithine Transcarbamylase (OTC) Deficiency
January 02, 2019 07:00 ET
|
Arcturus Therapeutics, Inc.
SAN DIEGO, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards rare,...
Arcturus Therapeutics to Host a Key Opinion Leader Call on Ornithine Transcarbamylase (OTC) Deficiency on December 11
December 03, 2018 07:00 ET
|
Arcturus Therapeutics, Inc.
SAN DIEGO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards rare,...
Arcturus Therapeutics Provides Corporate Update and Reports Third Quarter 2018 Financial Results
November 07, 2018 07:00 ET
|
Arcturus Therapeutics, Inc.
SAN DIEGO, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards rare,...
Arcturus Therapeutics Hosts Ribbon Cutting Ceremony for its Research and Development Facility
November 05, 2018 07:00 ET
|
Arcturus Therapeutics, Inc.
SAN DIEGO, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company, will officially cut the ribbon on its San Diego based research and...
Arcturus Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
October 01, 2018 07:09 ET
|
Arcturus Therapeutics, Inc.
SAN DIEGO, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards rare,...
Arcturus Therapeutics to Present at October Investor Conferences
September 25, 2018 07:00 ET
|
Arcturus Therapeutics, Inc.
SAN DIEGO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company, today announced that Joseph Payne will present at four investor conferences...
Arcturus Therapeutics Expands Management Team
September 21, 2018 07:00 ET
|
Arcturus Therapeutics, Inc.
Arcturus Appoints Senior VP of Business Development & Alliance Management and VP of Translational Biology SAN DIEGO, Sept. 21, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ:...